Similarly, in a cohort of EGFR-mutated NSCLC patients, the EGFR mutation was detected in 100% (26/26) of ctDNA-CSF samples, however only 84.6% (22/26) and 73.1% (19/26) of pelleted CSF and plasma ctDNA samples, respectively, identified the mutation (4). This evidence concerns the gene EGFR and non-small cell lung carcinoma.